Fig. 11
In vivo Anti-tumor efficacy of parental Tb535H, 53L1 and 53L10 novel tribodies. Tumor growth curves of A-549 subcutaneous tumors treated in the presence of human PBMCs with (A) parental Tb535H, (B) 53L1, and (C) 53L10 at two different doses (〇: 2 μg/mouse treatment, △: 20 μg/mouse treatment). ●: vehicle (PBS) treatment. Five × 106 cells of A-549 cells were subcutaneously transplanted into right flank of NOD-scid mice together with equal number of human activated PBMC (hPBMC). hPBMC were stimulated with Dynabeads Human T-Activator CD3/CD28 (Veritas) for 4 days before the transplantation. Intravenous treatment of indicated samples at the indicated dosage were performed at day 0, 2, 4, 6, 8, 10 (total 6 treatment) after the cell transplantation. Tumor volumes were expressed as mean ± standard deviation (SD). *P < 0.05 by Dunnett test (vs vehicle treatment group)